drugset / Trial / NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Timeline
- Start
- 2026-08-04
- Primary completion
- 2029-01-18
- Completion
- 2030-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | 9 mg/kg | — |
| Background | Avatrombopag | Small molecule | — | — |
| Background | Eltrombopag | Small molecule | — | — |
| Background | Romiplostim | Peptide | — | — |